IOVA
Iovance Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.79
+1.03%Year over year
Reported trailing growth
- Revenue
- +34.5%
- EBITDA
- +26.5%
- EBIT
- +26.6%
- EPS
- +43.1%
- Free cash flow
- +8.4%
- Operating cash flow
- +12.9%
Forward estimates
Based on analyst estimates
- Revenue
- +49.1%
- EBITDA
- +55.5%
- EPS
- +48.0%
Three-year CAGR
- Revenue
- +1388.7%
- EBITDA
- -7.8%
- EBIT
- -2.0%
- Net income
- -5.1%
- EPS
- +14.8%
- Free cash flow
- +7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026